• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    2/21/24 12:31:07 PM ET
    $BSGM
    $CYH
    $EBS
    $IOVA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $BSGM alert in real time by email

    Gainers

    • Emergent BioSolutions (NYSE:EBS) stock increased by 77.0% to $2.69 during Wednesday's regular session. The market value of their outstanding shares is at $139.5 million.
    • Ventyx Biosciences (NASDAQ:VTYX) shares moved upwards by 72.07% to $5.14. The market value of their outstanding shares is at $303.8 million.
    • Motus GI Hldgs (NASDAQ:MOTS) stock increased by 54.07% to $1.0. The company's market cap stands at $1.5 million.
    • Janux Therapeutics (NASDAQ:JANX) shares increased by 35.54% to $13.5. The market value of their outstanding shares is at $623.2 million.
    • RAPT Therapeutics (NASDAQ:RAPT) stock rose 26.05% to $8.66. The company's market cap stands at $297.8 million.
    • Iovance Biotherapeutics (NASDAQ:IOVA) stock rose 24.1% to $14.93. The company's market cap stands at $3.8 billion.

    Losers

    • BioSig Technologies (NASDAQ:BSGM) shares fell 29.2% to $0.37 during Wednesday's regular session. The market value of their outstanding shares is at $3.4 million.
    • PHAXIAM Therapeutics (NASDAQ:PHXM) shares decreased by 26.33% to $2.79. The company's market cap stands at $16.9 million.
    • Community Health Sys (NYSE:CYH) stock decreased by 25.87% to $3.0. The company's market cap stands at $409.7 million. The company's, Q4 earnings came out yesterday.
    • Teladoc Health (NYSE:TDOC) shares fell 25.21% to $15.32. The company's market cap stands at $2.5 billion. The company's, Q4 earnings came out yesterday.
    • Kazia Therapeutics (NASDAQ:KZIA) shares declined by 24.39% to $0.3. The market value of their outstanding shares is at $7.9 million.
    • NKGen Biotech (NASDAQ:NKGN) stock decreased by 20.64% to $1.0. The company's market cap stands at $21.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BSGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSGM
    $CYH
    $EBS
    $IOVA

    CompanyDatePrice TargetRatingAnalyst
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    RAPT Therapeutics Inc.
    $RAPT
    1/9/2026$95.00Overweight
    Piper Sandler
    Teladoc Health Inc.
    $TDOC
    12/9/2025$8.50Equal Weight
    Barclays
    Janux Therapeutics Inc.
    $JANX
    11/18/2025Peer Perform
    Wolfe Research
    Teladoc Health Inc.
    $TDOC
    11/13/2025$8.00Market Perform
    BMO Capital Markets
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $BSGM
    $CYH
    $EBS
    $IOVA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Community Health Systems Inc.

    DEFA14A - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    4/2/26 4:35:02 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    SEC Form DEF 14A filed by Community Health Systems Inc.

    DEF 14A - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    4/2/26 4:30:35 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Community Health Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Other Events

    8-K - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Filer)

    4/1/26 4:30:10 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teladoc upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Teladoc from Hold to Buy and set a new price target of $11.00

    3/10/26 8:39:03 AM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc upgraded by BofA Securities with a new price target

    BofA Securities upgraded Teladoc from Neutral to Buy and set a new price target of $7.00

    2/26/26 12:11:08 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Williams Paul Anthony

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    4/3/26 4:05:55 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Catapano Joseph Ronald

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    4/3/26 3:58:27 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Salka Susan R

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    4/1/26 4:04:59 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Community Health Systems Completes Divestiture of Huntsville, Alabama, Hospital to Huntsville Hospital Health System

    Community Health Systems, Inc. (NYSE:CYH) announced today that a subsidiary of the Company has completed the divestiture of substantially all of the assets of 180-bed Crestwood Medical Center in Huntsville, Alabama, and its associated outpatient centers and practices, to Huntsville Hospital Health System for $459 million, before certain transaction expenses. The entry into the definitive agreement for this transaction was announced on January 20, 2026, and the closing was effective April 1, 2026. This transaction is among the additional potential divestitures discussed on the Company's fourth quarter and end of year 2025 earnings call and in subsequent public appearances. Leerink Partne

    4/1/26 9:00:00 AM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. "This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnersh

    4/1/26 8:01:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    6/6/25 4:05:31 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Leadership Updates

    Live Leadership Updates

    View All

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teladoc Health Reports Fourth Quarter and Full Year 2025 Results

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ("Full Year 2024"). Highlights Fourth Quarter 2025 revenue of $642.3 million, flat year-over-year, and Full Year 2025 revenue of $2,530.0 million, down 2% year-over-yearFourth Quarter 2025 net loss of $25.1 million, or $0.14 per share, and Full Year 2

    2/25/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors

    NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa

    2/18/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $BSGM
    $CYH
    $EBS
    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Community Health Systems Inc.

    SC 13G/A - COMMUNITY HEALTH SYSTEMS INC (0001108109) (Subject)

    11/14/24 5:52:10 PM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care